MAPS PBC focuses on developing MDMA-assisted therapy as a breakthrough treatment for posttraumatic stress disorder (PTSD) and plans to seek FDA approval in 2023. Their successful Phase 3 clinical trial results were recently published in Nature Medicine and featured in The New York Times. Established in 2014 as a public benefit corporation, MAPS PBC prioritizes public benefit over profit. It is a subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization that has been working for over three decades to develop medical, legal, and cultural frameworks for the responsible use of psychedelics and marijuana. The company operates as a distributed team, utilizing technology and occasional in-person gatherings for collaboration.